Skip Navigation



NDT Advance Access published online on November 5, 2008

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn588
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/3/990    most recent
gfn588v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Reuter, S. E.
Right arrow Articles by Evans, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reuter, S. E.
Right arrow Articles by Evans, A. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients

Stephanie E. Reuter1, Randall J. Faull2, Enzo Ranieri3 and Allan M. Evans1

1 Sansom Institute, University of South Australia 2 Department of Renal Medicine, Royal Adelaide Hospital 3 Department of Genetic Medicine, Women's and Children's Hospital, Adelaide, SA, Australia

Correspondence and offprint requests to: Allan M. Evans, Sansom Institute, University of South Australia, GPO Box 2471, Adelaide, SA 5000, Australia. Tel: +61-8-8302-2310; Fax: +61-8-8302-2389; E-mail: allan.evans{at}unisa.edu.au



  Abstract

Background. Anaemia is a common complication associated with haemodialysis and is usually managed by treatment with recombinant human erythropoietin (rHuEPO). However, many patients remain hyporesponsive to rHuEPO treatment despite adequate iron therapy. The effect of L-carnitine administration on rHuEPO dose and/or haematocrit in haemodialysis patients has been previously reported with equivocal results. This study examined the relationship between endogenous carnitine pool composition and rHuEPO requirements in long-term haemodialysis patients.

Methods. Pre-dialysis blood samples were collected from 87 patients and analysed for plasma L-carnitine and individual acylcarnitine levels by LCMS/MS. As an indication of rHuEPO responsiveness, erythropoietin resistance index (ERI) was calculated as rHuEPO dose/kg/week normalized for haemoglobin levels.

Results. A significant negative correlation between L-carnitine levels and ERI was found (P = 0.0421). All patients categorized as high ERI (>0.02 µg/kg/week/gHb) exhibited subnormal L-carnitine levels (<30 µM); conversely, patients with normal L-carnitine levels (>30 µM) displayed low ERI values (<0.02 µg/kg/week/gHb). More importantly, the ratio of non-acetyl acylcarnitines/total carnitine was significantly positively correlated with ERI (P = 0.0062).

Conclusions. These data illustrate the relationship between carnitine levels and response to rHuEPO treatment in haemodialysis patients, in particular, the importance of the proportion of long-chain acylcarnitines within the plasma carnitine pool. This proportion may be more indicative of the response to L-carnitine supplementation than absolute L-carnitine levels alone.

Keywords: acylcarnitine; anaemia; erythropoietin; haemodialysis; L-carnitine

Received for publication: 15. 1.08
Accepted in revised form: 26. 9.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.